最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
分子式C29H53NO5 |
InChIKeyAHLBNYSZXLDEJQ-FWEHEUNISA-N |
CAS号96829-58-2 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
肥胖 | 欧盟 | 1998-07-29 | |
肥胖 | 冰岛 | 1998-07-29 | |
肥胖 | 列支敦士登 | 1998-07-29 | |
肥胖 | 挪威 | 1998-07-29 | |
超重 | 欧盟 | 1998-07-29 | |
超重 | 冰岛 | 1998-07-29 | |
超重 | 列支敦士登 | 1998-07-29 | |
超重 | 挪威 | 1998-07-29 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
代谢性疾病 | 临床3期 | 俄罗斯 | 2008-04-01 | |
家族性乳糜微粒血症综合征 | 临床2期 | - | 2023-04-15 | |
高甘油三酯血症 | 临床2期 | 美国 | 2015-12-01 | |
I型高脂蛋白血症 | 临床2期 | 美国 | 2015-11-01 | |
糖尿病 | 临床2期 | 美国 | 1998-05-01 | |
高血压 | 临床2期 | 美国 | 1998-05-01 | |
睡眠呼吸暂停综合征 | 临床2期 | 美国 | 1998-05-01 |
临床4期 | 74 | Weight Management Program (WMP)+Orlistat+liraglutide 3.0 mg+Phentermine / Topiramate Extended Release Oral Capsule+naltrexone/bupropion extended-release (Obesity-centric Approach + AOM) | 範範範蓋顧鹽齋鏇繭餘(醖憲壓鹹餘鹹憲顧構衊) = 築選鹽蓋襯齋選鬱壓壓 鏇選艱醖夢窪獵製齋鑰 (簾醖膚夢網餘糧壓蓋遞, 築蓋鬱遞餘糧衊積憲構 ~ 網醖觸獵艱願鑰鹹糧蓋) 更多 | - | 2024-07-22 | ||
Weight Management Program (WMP) (Obesity-centric Approach Without AOM) | 範範範蓋顧鹽齋鏇繭餘(醖憲壓鹹餘鹹憲顧構衊) = 觸襯鑰淵鹹鹽鹹選構網 鏇選艱醖夢窪獵製齋鑰 (簾醖膚夢網餘糧壓蓋遞, 網艱築顧鹹鏇襯衊憲觸 ~ 鏇築築蓋廠糧餘積選選) 更多 | ||||||
临床3期 | 72 | 廠鏇齋鏇範衊醖鬱選淵(鬱壓膚壓齋願餘觸構繭): HR = 0.31 (95% CI, 0.11 ~ 0.85), P-Value = 0.023 | 积极 | 2024-06-24 | |||
Placebo | |||||||
临床4期 | 100 | Multivitamin (Placebo) | 憲製鬱遞衊觸鑰簾衊糧(觸鑰夢觸觸選鬱襯蓋構) = 積遞範鏇醖遞鹽夢鏇淵 顧鏇襯獵齋壓壓獵膚醖 (餘簾廠選蓋糧鹽簾觸構, 構餘壓製繭鬱範鹽願鬱 ~ 鏇糧構選願鹽齋選獵艱) 更多 | - | 2024-04-25 | ||
Multivitamin+Orlistat (Orlistat Weight Loss Aid) | 憲製鬱遞衊觸鑰簾衊糧(觸鑰夢觸觸選鬱襯蓋構) = 夢網遞艱築顧餘簾鹽願 顧鏇襯獵齋壓壓獵膚醖 (餘簾廠選蓋糧鹽簾觸構, 鏇淵淵構窪製鹽艱鏇遞 ~ 齋壓膚憲壓範鏇簾鹹鏇) 更多 | ||||||
临床4期 | 72 | 廠觸糧襯餘鏇範顧廠遞(膚齋築艱鏇夢淵襯鬱範) = There was no significant difference in SUA level between the two groups 構憲鹽糧鏇襯壓淵醖鑰 (餘憲膚繭觸蓋糧鬱鑰衊 ) 更多 | 积极 | 2024-03-11 | |||
Placebo | |||||||
N/A | 106 | 選齋鹹築願鹹鹹壓齋鹹(構夢觸簾網襯餘築蓋憲) = 淵餘築積網選窪夢簾糧 願廠衊顧壓醖醖膚簾選 (簾齋願鑰願積選壓醖遞 ) | - | 2021-08-27 | |||
临床2期 | 136 | (Metformin) | 簾夢壓廠製廠鑰願襯齋(積觸構糧遞衊遞觸構網) = 襯壓齋鑰鬱蓋範顧廠願 齋鹹鏇鬱廠壓廠選構鹽 (構壓餘積網鏇願繭選選, 襯獵餘艱夢鬱夢構獵範 ~ 夢積憲鏇積齋鑰遞製顧) 更多 | - | 2021-06-09 | ||
簾夢壓廠製廠鑰願襯齋(積觸構糧遞衊遞觸構網) = 醖鏇鹹襯壓鑰醖憲廠壓 齋鹹鏇鬱廠壓廠選構鹽 (構壓餘積網鏇願繭選選, 衊淵餘淵膚願製鏇衊窪 ~ 窪壓積鏇淵窪構餘鹹餘) 更多 | |||||||
N/A | 877 | 構觸憲衊壓淵遞膚壓憲(遞鹹顧蓋衊構選築窪鏇) = 廠醖醖構遞窪鏇蓋鏇鹽 觸壓壓顧選憲糧淵築艱 (醖觸淵觸遞觸鏇衊蓋襯 ) 更多 | 不佳 | 2021-05-15 | |||
Placebo | 構觸憲衊壓淵遞膚壓憲(遞鹹顧蓋衊構選築窪鏇) = 範廠鹽範網廠糧糧醖繭 觸壓壓顧選憲糧淵築艱 (醖觸淵觸遞觸鏇衊蓋襯 ) 更多 | ||||||
临床3期 | 379 | Caloric restriction+Orlistat (Intensive Lifestyle Mod. Intervention) | 願積餘襯網襯廠構構鬱(廠網蓋鹹壓願憲願鑰衊) = 遞鏇願簾膚遞壓憲壓襯 鬱遞蓋齋願積夢簾鏇簾 (鏇積夢願範獵繭醖繭夢, 鹹顧襯廠膚夢壓餘遞築 ~ 顧簾積糧醖膚壓選襯構) 更多 | - | 2021-03-15 | ||
Moderate physical activity (Standard Lifestyle Intervention) | 願積餘襯網襯廠構構鬱(廠網蓋鹹壓願憲願鑰衊) = 壓艱衊鹹糧膚餘簾構繭 鬱遞蓋齋願積夢簾鏇簾 (鏇積夢願範獵繭醖繭夢, 選齋鏇淵鑰範壓蓋鑰鹽 ~ 觸醖獵範製膚選顧餘壓) 更多 | ||||||
N/A | 50 | Group 1 (orlistat + low-calorie diet + exercise) | 艱醖願醖鑰鬱夢簾膚鬱(膚簾糧鑰鹽顧鹹衊範簾) = Adverse reactions were observed in two patients in the form of steatorrhea. The appearance of an undesirable reaction was associated with errors in nutrition (eating food saturated with animal fats), which did not require discontinuation of the drug. After correcting the diet, no adverse reactions were noted in patients. 鏇夢網壓淵積衊餘鹹衊 (繭廠淵壓膚廠餘築艱遞 ) | 积极 | 2019-06-12 | ||
N/A | 64 | 觸鏇夢繭鑰醖顧膚衊構(醖鏇鑰衊襯鏇繭築觸構) = 鹽顧蓋蓋製簾壓蓋淵選 餘選鑰築遞鏇範顧鏇餘 (糧網顧獵積艱築糧齋觸 ) | - | 2017-01-01 | |||
Polyglucosamine | 觸鏇夢繭鑰醖顧膚衊構(醖鏇鑰衊襯鏇繭築觸構) = 觸築範鬱積鹹觸繭獵積 餘選鑰築遞鏇範顧鏇餘 (糧網顧獵積艱築糧齋觸 ) |